Elevating Oncology Clinical Trials: Biotech, Pharma, and Medical Device Firms Outsourcing to CROs

What are Oncology Clinical Trials?

Oncology clinical trials are research studies that test new cancer treatments in people. These trials can help doctors find new ways to improve cancer patients’ treatment and quality of life.

Several oncology clinical trials are based on discovering new drugs, while others test new combinations of existing drugs. Some studies test new ways to deliver cancer treatments, such as gene therapy or immunotherapy.  

The Global Oncology Clinical Trials Market

The Oncology Clinical Trials Market is expected to register a parallel growth alongside the Global Market for Clinical Trials, which had a valuation of USD 54.24 billion in 2022 and is forecasted to reach USD 92.45 billion in 2023, with a compound annual growth rate (CAGR) of 6.9%. 

According to a market research report by Mordor Intelligence, for the studied period 2023-2028, the Global Oncology Clinical Trials Market is projected to have a CAGR of 5.4% and reach a total valuation of USD 16.63 billion by 2028, according to Business Wire. The largest market for oncology clinical trials is the North American market, whereas the fastest-growing region is Asia-Pacific, with a CAGR of 7.4%. Several reasons behind this emerging market are the rising cancer incidence, increased investment in R&D, government support, and technological advancements.

The Role of CROs for Biotechnology, Pharmaceutical, and Medical Device Companies in Oncology Clinical Trials

CROs are invaluable partners for biotechnologypharmaceutical, and medical device companies in the field of oncology clinical trials. They offer expertise, efficiency, and resources that can significantly enhance the success and speed of clinical research in the challenging and ever-evolving landscape of cancer treatment development.

Oncology CRO for Pharmaceutical Companies: 

Pharmaceutical companies play a critical role in developing new cancer treatments. However, in most cases, they cannot succeed alone. CROs 

For a specific instance, a CRO can help a pharmaceutical company design and conduct a clinical trial to evaluate the safety and efficacy of a new drug for the treatment of lung cancer. The CRO would work with the pharmaceutical company to develop a protocol with appropriate endpoints, statistical methods, and risk management strategies. The CRO would also help the pharmaceutical company to select clinical trial sites and recruit patients.

Moreover, a CRO can help a pharmaceutical company conduct a clinical trial to evaluate the safety and efficacy of a new immunotherapy for treating melanoma and a new gene therapy for treating leukemia.

Oncology CRO for Biotechnology Companies:

Biotechnology companies are at the forefront of cancer research, developing novel therapies and treatments that have the potential to revolutionize the way cancer is treated. CROs play a vital role in supporting biotechnology companies in their oncology clinical trials, helping them to design, conduct, and analyze their trials efficiently and effectively, reducing costs, managing risks, and focusing on data-driven decision-making in clinical research. 

A CRO plays a pivotal role in assisting biotechnology companies in designing and conducting clinical trials for innovative cancer treatments, such as gene therapy for brain cancer, immunotherapy for pancreatic cancer, and targeted cure for breast cancer. The CRO collaborates with biotechnology companies to craft comprehensive trial protocols encompassing relevant endpoints, statistical methodologies, and risk mitigation strategies. Additionally, the CRO aids in the critical tasks of site selection and patient recruitment, streamlining the entire process for effective evaluation of safety and treatment efficacy in these diverse oncology trials.

Oncology CRO for Medical Devices:

Oncology clinical trials are a critical component of medical device development in the field of cancer care. CROs play a vital role in supporting medical device sponsors throughout this process. CROs provide specialized services that help expedite the design, avoid critical mistakes, and ensure the successful execution of oncology clinical trials for medical devices.

CROs are instrumental in assisting medical device companies in designing and conducting clinical trials for a range of innovative devices, including implantable devices for liver cancer treatment, diagnostic devices for early lung cancer detection, and surgical devices for pancreatic cancer treatment. These organizations collaborate closely with medical device companies to develop comprehensive trial protocols, including defining appropriate endpoints, statistical methodologies, and risk management strategies. Furthermore, CROs play a crucial role in selecting clinical trial sites and recruiting patients, ensuring that the safety and efficacy of these cutting-edge medical devices are rigorously evaluated in diverse oncology contexts.

Summary

Oncology clinical trials are a critical part of cancer research, offering new treatments and hope for patients. The global market for these trials is growing steadily, especially in Asia-Pacific. Contract Research Organizations (CROs) are essential partners for pharmaceutical, biotech, and medical device companies, helping them develop innovative cancer therapies. With CROs guiding the process from trial design to patient recruitment, the future of cancer treatment looks more promising than ever, giving new hope to those fighting this challenging disease.

Sources:

  • Mordor Intelligence – “ONCOLOGY CLINICAL TRIALS MARKET SIZE & SHARE ANALYSIS – GROWTH TRENDS & FORECASTS (2023 – 2028)”
  • Business Wire – “Global $16.63 Billion Oncology Clinical Trials Markets to 2028 by Phase; Study Design; Cancer Type; Competitive Landscape”
  • Grand View Research – “Oncology Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional, Observational, Expanded Access), By Cancer Type, By Region, And Segment Forecasts, 2020 – 2027”